Home › Funds › Cormorant Asset Management, LP › AMLX

Cormorant Asset Management, LP position in AMLX

AMYLYX PHARMACEUTICALS INC · Health Care

Cormorant Asset Management, LP reported holding 300,000 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$8.7M, representing 0.62% of its reported portfolio and ranking #37 among its reported holdings. Cormorant Asset Management, LP has disclosed AMLX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)300.00K sh
Reported value held$8.73M
Portfolio Weight0.62%
First reportedQ3 2025
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Cormorant Asset Management, LP's AMLX position evolved

Cormorant Asset Management, LP first disclosed a stake in AMLX in Q3 2025 at 500,000 shares (US$6.8M). The position peaked in Q3 2026 at 300,000 shares, worth US$8.7M. Across 5 filings, Cormorant Asset Management, LP increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 300,000 shares valued at US$8.7M — an increase of 100,000 shares quarter over quarter.. Notable position changes include a 43% trim in Q2 2026 (shares rose 62% over the following quarter), a 50% increase in Q3 2026 (shares fell 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 500.00K $6.79M New
Q4 2025 400.00K $4.83M Reduce
Q1 2026 350.00K $4.87M Reduce
Q2 2026 200.00K $3.59M Reduce
Q3 2026 300.00K $8.73M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AMLX and 13F data

AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 53 other funds we track also report a position in AMLX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$307.7M), TCG Crossover Management, LLC (US$181.7M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$158.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AMLX

All AMLX fund holders →

FAQ

How long has Cormorant Asset Management, LP held AMLX?

Cormorant Asset Management, LP has disclosed AMLX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

What is Cormorant Asset Management, LP's current position in AMLX?

As of Q3 2026, Cormorant Asset Management, LP holds 300.00K shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $8.73M, representing 0.62% of its reported portfolio and ranking #37.

Has Cormorant Asset Management, LP been buying or selling AMLX?

In the latest 13F filing (Q3 2026), Cormorant Asset Management, LP increased its position in AMLX. The position peaked in Q3 2026 at 300.00K shares.

Which other funds hold AMLX?

Other major institutional holders of AMLX include PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, among 53 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.